In an effort to identify factors responsible for the maintenance of the anergic phenotype we employed a novel statistical algorithm, HAM (Hypothesis based Analysis of Microarrays) to interrogate a data base consisting of T cell stimulated under conditions that either promote full T cell activation or anergy. Among the genes identified by this approach was Sprouty 1 a member of an evolutionarily conserved family of inducible inhibitors that has been mostly studied in the field of Development. In particular Sprouty 1 has been implicated in negative feedback loops that impart spatial temporal constraints to intracellular signals. In this project we will dissect the mechanism by which Sprouty 1 inhibits T cell activation and maintains the anergic state.
In Aim I we will determine the mechanisms governing the expression of Sprouty 1 and the precise biochemical mechanisms by which Sprouty 1 inhibits TCR-induced signaling.
In Aim II, in collaboration with Project 2, we will determine how the structure and intracellular trafficking of Sprouty 1 dictates its inhibitory function.
In Aim III using conditional Sprouty 1 null mice we will determine the role of Sprouty 1 in regulating viral, """"""""self and tumor immune responses in vivo. Overall dissecting the mechanisms by which Sprouty 1 inhibits T cell function should provide important insight in terms of identifying novel pharmacologic targets. For example in autoimmune diseases and transplantation, the goal would be to inhibit T cell activation but leave Sprouty 1 signaling intact. Alternatively, for tumor immunity, developing strategies to inhibit Sprouty 1 function and thus enhance the anti-tumor response.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI072677-05
Application #
8381800
Study Section
Special Emphasis Panel (ZAI1-PA-I)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$298,453
Indirect Cost
$96,147
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bettencourt, Ian A; Powell, Jonathan D (2017) Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation. J Immunol 198:999-1005
Kosmides, A K; Meyer, R A; Hickey, J W et al. (2017) Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials 118:16-26
Tiper, Irina V; Temkin, Sarah M; Spiegel, Sarah et al. (2016) VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clin Cancer Res 22:4249-58
Pollizzi, Kristen N; Sun, Im-Hong; Patel, Chirag H et al. (2016) Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation. Nat Immunol 17:704-11
Schütz, Christian; Varela, Juan Carlos; Perica, Karlo et al. (2016) Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget 7:68503-68512
Pollizzi, Kristen N; Waickman, Adam T; Patel, Chirag H et al. (2015) Cellular size as a means of tracking mTOR activity and cell fate of CD4+ T cells upon antigen recognition. PLoS One 10:e0121710
Makowski, Stefanie L; Wang, Zhaoquan; Pomerantz, Joel L (2015) A protease-independent function for SPPL3 in NFAT activation. Mol Cell Biol 35:451-67
Shaikh, Saame Raza; Boyle, Sarah; Edidin, Michael (2015) A high fat diet containing saturated but not unsaturated fatty acids enhances T cell receptor clustering on the nanoscale. Prostaglandins Leukot Essent Fatty Acids 100:1-4
Pollizzi, Kristen N; Patel, Chirag H; Sun, Im-Hong et al. (2015) mTORC1 and mTORC2 selectively regulate CD8? T cell differentiation. J Clin Invest 125:2090-108
Perica, Karlo; Bieler, Joan Glick; Schütz, Christian et al. (2015) Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano 9:6861-71

Showing the most recent 10 out of 34 publications